Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients

about

Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients

Item

http://www.wikidata.org/entity/Q37013494

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Efficacy of plasmapheresis on ...... t-kidney transplant recipients

@en

Efficacy of plasmapheresis on ...... -kidney transplant recipients.

@nl

type

Item

label

Efficacy of plasmapheresis on ...... t-kidney transplant recipients

@en

Efficacy of plasmapheresis on ...... -kidney transplant recipients.

@nl

prefLabel

Efficacy of plasmapheresis on ...... t-kidney transplant recipients

@en

Efficacy of plasmapheresis on ...... -kidney transplant recipients.

@nl

P1476

Efficacy of plasmapheresis on ...... t-kidney transplant recipients

@en

P2093

Alan B Leichtman

http://www.w3.org/2001/XMLSchema#string

Chisa Yamada

http://www.w3.org/2001/XMLSchema#string

Daniel S Ramon

http://www.w3.org/2001/XMLSchema#string

Marilia Cascalho

http://www.w3.org/2001/XMLSchema#string

Milagros Samaniego

http://www.w3.org/2001/XMLSchema#string

Randall S Sung

http://www.w3.org/2001/XMLSchema#string

Robertson D Davenport

http://www.w3.org/2001/XMLSchema#string

P2860

Proteasome inhibitor-based therapy for antibody-mediated rejection

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

Exogenous immunoglobulin downregulates T-cell receptor signaling and cytokine production.

Plasmapheresis adjusts inflammatory responses in potential kidney transplant recipients.

Efficacy of anti-interleukin-2 receptor antibody (daclizumab) in reducing the incidence of acute rejection after renal transplantation.

New approaches for detecting complement-fixing antibodies.

The role of complement in antibody-mediated rejection in kidney transplantation.

The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.

The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.

Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection.

P304

727-35; quiz 726

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/TRF.12923

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268156618

http://www.w3.org/2001/XMLSchema#string

P698

25385678

http://www.w3.org/2001/XMLSchema#string

P932

4911015

http://www.w3.org/2001/XMLSchema#string